Article thumbnail

Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors†

By Rafaela S. Ferreira, Anton Simeonov, Ajit Jadhav, Oliv Eidam, Bryan T. Mott, Michael J. Keiser, James H. McKerrow, David J. Maloney, John J. Irwin and Brian K. Shoichet
Topics:
Publisher: American Chemical Society
OAI identifier: oai:pubmedcentral.nih.gov:2895358
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2002). A common mechanism underlying promiscuous inhibitors from virtual and high-throughput
  2. (2002). A model binding site for testing scoring functions in molecular docking.
  3. (2005). ALARMNMR:arapidandrobustexperimentalmethodtodetect reactive false positives in biochemical screens.
  4. (2004). Automated protein crystal structure determination using ELVES.
  5. (1987). Calculation of electrostatic potentials in an enzyme active site.
  6. (2007). Classification of water molecules in protein binding sites.
  7. (2005). Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3β inhibitors.
  8. (2008). Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase.
  9. (2006). Contribution of Conformer Focusing to the Uncertainty in Predicting Free Energies for Protein-Ligand Binding.
  10. (2004). Coot: model-building tools for molecular graphics.
  11. (1998). Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.
  12. (2001). Detailed analysis of scoring functions for virtual screening.
  13. (2004). Detailed kinetic studies of an aggregating inhibitor: inhibition of phosphomannomutase/phosphoglucomutase by Disperse Blue 56. Biochemistry
  14. (2002). Development of a virtual screening method for identification of “frequent hitters” in compound libraries.
  15. (2009). Divergent Modes of Enzyme Inhibition in a Homologous Structure-Activity Series.
  16. (2003). Effect of detergent on “promiscuous” inhibitors.
  17. (2004). Exploring biology with small organic molecules.
  18. (2008). Fluorescence spectroscopic profiling of compound libraries.
  19. (2005). Hierarchical docking of databases of multiple ligand conformations.
  20. (2008). Identification of a new class of nonpeptidic inhibitors of cruzain.
  21. Importance of ligand reorganization free energy in protein-ligand bindingaffinityprediction.J.Am.Chem.Soc.2009,131,13709–13721.
  22. (2006). Integration of virtual and physical screening. Drug Discovery Today: Technol.
  23. (2005). Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists.
  24. (2006). Interpreting steep dose-response curves in early inhibitor discovery.
  25. (2005). Irwin,J.J.;Shoichet,B.K.ZINC;afreedatabaseofcommercially available compounds for virtual screening.
  26. (2009). J.H.;Brinen,L.S.;Renslo,A.R.Novelnon-peptidicvinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases.
  27. (1998). L.A.Screeningapeptidyldatabaseforpotentialligandstoproteins with side-chain flexibility. Proteins
  28. (1999). Ligand solvation in molecular docking. Proteins
  29. (2002). Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B.
  30. (2007). Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding.
  31. (2004). Navigating chemical space for biology and medicine. Nature
  32. (2006). Novel procedure for modeling ligand/receptor induced fit effects.
  33. (2002). PHENIX: building new software for automated crystallographic structure determination.
  34. (2009). Predicting new molecular targets for known drugs. Nature
  35. (2009). Prediction of the water content in protein binding sites.
  36. (1993). Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi.
  37. (2008). Quantifying the relationships among drug classes.
  38. Quantitative Analyses of Aggregation, Autofluorescence, and Reactivity Artifacts in a Screen for Inhibitors of a Thiol Protease.
  39. (2010). Reactive compounds and in vitro false positives in HTS. Drug Discovery Today 1997, 2, 382–384.Article
  40. (1999). Recognizing molecules with drug-like properties.
  41. (2007). Relating protein pharmacology by ligand chemistry. Nature Biotechnol.
  42. (2005). Representing receptor flexibility in ligand docking through relevant normal modes.
  43. (2007). Shoichet,B.K.;Austin,C.P.Ahigh-throughputscreenforaggregation-based inhibition in a large compound library.
  44. (1997). Structural determinants of specificity in the cysteine protease cruzain. Protein Sci.
  45. (2009). Structure-based discovery of β2-adrenergic receptor ligands.
  46. (2008). Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors.
  47. (1994). The CCP4 suite: programs for protein crystallography.
  48. (2002). The Pymol Molecular Graphics System; DeLano Scientific:
  49. (2005). Utilization of NMR-derived fragment leads in drug design. Methods Enzymol.
  50. Virtual and biomolecular screening converge on a selective agonist for GPR30.
  51. (2004). Virtual screening using protein-ligand docking: avoiding artificial enrichment.
  52. (2003). Walters,W.P.;Namchuk,M.Aguidetodrugdiscovery.Designing screens: how to make your hits a hit. Nature Rev. Drug Discovery
  53. (2006). Yasgar,A.;Zheng,W.;Austin,C.P.Quantitativehigh-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.